Please Wait...

NTX-I // N-Terminal Crosslinked Telopeptide of Type I Collagen

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

In bone, type I collagen constitute 90% of the organic matrix. Markers of bone resorption in serum or urine can be used to assess changes in bone resorption in various bone diseases or under treatment (Naylor and Eastell, 2012). Cross linked amino-terminal collagen (NTx-I) are peptides derived from the degradation of collagen I. Measurement of these peptides in urine or serum provide information about the bone resorption rate. The specific assay for NTx peptides have been developed in the nineties and urine values have been found to correlate with HPLC measurements of urinary hydroxyproline or pyridinoline in patients with Paget's disease (Hanson et al., 1992). Different studies have since shown the pertinence of NTx measurement for assessing bone resorption rate in other diseases (Bettica et al., 2002; Clemens et al., 1997; Garnero et al., 1996).

Bioclinica Lab employs a manual sandwich immunoassay for measurement in urine (associated with creatinine values) or in serum.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @virtue_insight: #VIphv We are delighted to announce our new Gold Sponsor @bioclinica for our 16th Pharmacovigilance 2018 https://t.co/h…
bioclinica (5 hours ago)
RT @bioclinica: Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas R embra…
bioclinica (5 hours ago)
Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas… https://t.co/iW7Q9DfVgQ
bioclinica (6 days ago)
Background & key considerations to help #pharma prepare for new FDA blood pressure draft guidance issued in May. Ac… https://t.co/07dJeeD35E
bioclinica (2 weeks ago)
Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas… https://t.co/tSx5tm2rgg
bioclinica (3 weeks ago)
DYK @bioclinica offers full-svc global clinical data mgmt svcs customizable to your study & program needs? Our high… https://t.co/dyXDiCtWd8
bioclinica (3 weeks ago)

Latest Blogs:

Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations